CAR-T therapy for cancers spread to lining of lungs, belly, or brain
Part of Brain & nervous system, Cancer clinical trials.
This trial tests an experimental CAR-T cell treatment that targets proteins on cancer cells that have spread to the lining of the lungs, belly, or brain. It may help people whose cancer has not responded to standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old
- Your cancer has spread to the lining of the lungs, belly, or around the brain
- You have tried standard treatments and they didn't work, or for brain involvement, you had at least 3 spinal taps with persistent cancer cells
- You are generally able to care for yourself but may need some help
- Your heart, liver, and kidney function are within acceptable levels
- You have no active infections, severe autoimmune diseases, or other serious conditions
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase trial tests CAR-T cells designed to attack tumors that have high HER2 and PD-L1. It may help people with certain solid cancers that have not responded well to standard treatment.
This trial tests a new type of cell therapy (CAR-T) that targets two proteins, CLDN18.2 and PD-L1, found on some cancer cells. It is for people with advanced solid tumors like stomach, esophageal, or pancreatic cancer that have stopped responding to standard treatments.
This trial tests a new type of immune cell therapy (CAR-T cells) designed to target two markers on cancer cells at once. The goal is to help patients with advanced solid tumors where standard treatments have stopped working or aren't an option.
This Phase 1 study tests CAR-T cells that are engineered to recognize several cancer “markers” (specific proteins) found on some advanced cancers. It may help by directing the patient’s own immune cells to attack cancer, but eligibility depends on matching the required protein markers.
This trial tests a lab-made immune therapy (CAR-T) that targets a protein called CD70 found on some advanced cancers. It’s designed for people whose solid tumors have spread and no standard treatments have worked or weren’t tolerated.
This trial tests a new treatment called CAR-T cells that are designed to find and attack cancer cells carrying a protein called CEA. It is for people with advanced colorectal, esophageal, stomach, or pancreatic cancer who have already tried other treatments.
Hear when a new Malignant Ascites trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.